UA93085C2 - Inhibitors of c-fms kinase - Google Patents

Inhibitors of c-fms kinase

Info

Publication number
UA93085C2
UA93085C2 UAA200813399A UAA200813399A UA93085C2 UA 93085 C2 UA93085 C2 UA 93085C2 UA A200813399 A UAA200813399 A UA A200813399A UA A200813399 A UAA200813399 A UA A200813399A UA 93085 C2 UA93085 C2 UA 93085C2
Authority
UA
Ukraine
Prior art keywords
cancer
diseases
inflammatory
treating
osteoarthritis
Prior art date
Application number
UAA200813399A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Карл Р. Иллиг
Шелли К. БОЛЛЕНТАЙН
Цзиньшен Чень
Рене Луиз ДЕЖАРЛЕ
Санатх К. Мигалла
Брюс Э. Томчук
Марк УОЛЛ
Кеннет Уилсон
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of UA93085C2 publication Critical patent/UA93085C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
UAA200813399A 2006-04-20 2007-04-18 Inhibitors of c-fms kinase UA93085C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79366706P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
UA93085C2 true UA93085C2 (en) 2011-01-10

Family

ID=38472852

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200813399A UA93085C2 (en) 2006-04-20 2007-04-18 Inhibitors of c-fms kinase

Country Status (22)

Country Link
US (7) US8815867B2 (enExample)
EP (3) EP2016074B1 (enExample)
JP (3) JP5331679B2 (enExample)
KR (3) KR101367646B1 (enExample)
CN (1) CN101472914B (enExample)
AR (3) AR060611A1 (enExample)
AU (3) AU2007240443B2 (enExample)
BR (1) BRPI0710548B8 (enExample)
CA (3) CA2649924C (enExample)
ES (3) ES2566772T3 (enExample)
IL (1) IL194845A (enExample)
MX (3) MX2008013529A (enExample)
NO (1) NO20084896L (enExample)
NZ (3) NZ572072A (enExample)
PE (1) PE20080074A1 (enExample)
RU (1) RU2475483C2 (enExample)
SG (1) SG171593A1 (enExample)
TW (3) TWI411612B (enExample)
UA (1) UA93085C2 (enExample)
UY (1) UY30297A1 (enExample)
WO (3) WO2007124322A1 (enExample)
ZA (1) ZA200809873B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CN101534858A (zh) * 2006-01-05 2009-09-16 诺华有限公司 预防和治疗癌症转移和癌症转移相关性骨丢失的方法
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
ES2458291T3 (es) * 2006-04-20 2014-04-30 Janssen Pharmaceutica Nv Derivados de amidas aromáticas como inhibidores de la cinasa C-KIT
KR101367645B1 (ko) * 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
AU2007240439B2 (en) * 2006-04-20 2012-10-11 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
KR101367646B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
US10106798B2 (en) 2010-01-05 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
KR101938431B1 (ko) 2011-05-05 2019-01-14 노파르티스 아게 뇌 종양의 치료를 위한 csf-1r 억제제
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US9303046B2 (en) 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RS59007B1 (sr) * 2014-02-03 2019-08-30 Vitae Pharmaceuticals Llc Dihidropirolopiridinski inhibitori ror-gama
CN113620958A (zh) 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
PH12018500554B1 (en) 2015-09-14 2024-01-24 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
CN112441941B (zh) * 2020-12-03 2022-08-02 浙江荣耀生物科技股份有限公司 一种1-(4-氨基苯基)环戊基甲腈的制备方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2466420A (en) 1947-11-26 1949-04-05 Eastman Kodak Co Ketene condensation products with aldehydes
US3226394A (en) 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
US4551540A (en) 1983-01-17 1985-11-05 Borg-Warner Chemicals, Inc. Substituted 2,5-dimethylpyrroles
JPH0264704A (ja) 1988-08-30 1990-03-05 Honda Motor Co Ltd 自動化設備の制御システム
EP0358459B1 (en) 1988-09-08 1996-06-19 Sony Corporation Picture processing apparatus
JPH0299250A (ja) 1988-09-30 1990-04-11 Kobe Steel Ltd タンディッシュのスラグ除去方法
JP2833106B2 (ja) 1990-02-21 1998-12-09 株式会社島津製作所 液体クロマトグラフ
JPH03255915A (ja) 1990-03-07 1991-11-14 Nkk Corp 流量検出装置
US5190541A (en) 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
JPH04184937A (ja) 1990-11-20 1992-07-01 Oki Electric Ind Co Ltd 半導体集積回路装置の製造方法
JPH04212503A (ja) 1990-12-05 1992-08-04 Mitsubishi Electric Corp トリプレート線路共振器
JPH0821207B2 (ja) 1992-02-03 1996-03-04 日本コロムビア株式会社 ディスク装置
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
JPH05293265A (ja) 1992-04-17 1993-11-09 Juki Corp 千鳥縫いミシンの針振り駆動変更装置
JPH0815587B2 (ja) 1992-05-01 1996-02-21 東亜工業株式会社 振動ふるい
JPH05346639A (ja) 1992-06-15 1993-12-27 Konica Corp 写真処理廃液の再利用方法
JPH0684710A (ja) 1992-09-03 1994-03-25 Matsushita Electric Ind Co Ltd 電解コンデンサ
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP3243861B2 (ja) 1992-12-10 2002-01-07 ソニー株式会社 画像情報変換装置
KR100360206B1 (ko) 1992-12-10 2003-02-11 소니 가부시끼 가이샤 화상신호변환장치
JPH06189231A (ja) 1992-12-16 1994-07-08 Toshiba Corp 液晶表示装置
JP3522818B2 (ja) 1993-02-26 2004-04-26 富士写真フイルム株式会社 写真用支持体
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
JP3192537B2 (ja) 1993-11-18 2001-07-30 キヤノン株式会社 走査光学装置
JP3197737B2 (ja) 1994-02-15 2001-08-13 三洋電機株式会社 コインメカニズムの取付け装置
JPH07310319A (ja) 1994-05-19 1995-11-28 Katsuyuki Hasegawa 杭打ち装置及び杭打ちアタッチメント
JP3592748B2 (ja) 1994-07-01 2004-11-24 三菱重工業株式会社 蒸気、ガスタービン複合プラントの廃熱による蒸気生成システム
JPH08107715A (ja) 1994-10-13 1996-04-30 Iseki & Co Ltd コンバインの拡縮式グレンタンク装置
JPH10507185A (ja) 1994-10-14 1998-07-14 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ２−（イミダゾール−４−イル）カルバペネム誘導体、その中間体および抗菌剤としての使用
JP3357754B2 (ja) 1994-10-18 2002-12-16 三洋電機株式会社 疑似ステレオ画像生成方法及び疑似ステレオ画像生成装置
JPH08287118A (ja) 1995-02-16 1996-11-01 Fujitsu Ltd 部品標準化方式
JPH07322944A (ja) 1995-04-10 1995-12-12 Sanyo Electric Co Ltd 透視板
JPH10506560A (ja) 1995-04-19 1998-06-30 シュナイダー（ユーエスエー）インク 薬品を放出する被覆されたステント
US6117432A (en) 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
JP3415333B2 (ja) 1995-07-13 2003-06-09 トヨタ自動車株式会社 水素吸蔵合金
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EA000710B1 (ru) 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5702390A (en) 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
CA2262676A1 (en) 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
ATE252104T1 (de) 1996-12-20 2003-11-15 Tovarischestvo S Ogranichennoi Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12- lid- hydrochlorid
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
BR9809398A (pt) 1997-04-25 2000-06-13 Janssen Pharmaceutica Nv Quinazolinonas que inibem a farnesil transferase
TW491872B (en) 1997-05-27 2002-06-21 Ciba Sc Holding Ag Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
CA2322798C (en) 1998-03-05 2008-05-13 Formula One Administration Limited Data communication system
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU5086499A (en) 1998-07-01 2000-01-24 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
JP2002520324A (ja) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド 新規な血管形成インヒビター
US6284098B1 (en) * 1998-07-20 2001-09-04 Wwj, Llc Lignocellulose fiber filler for thermoplastic composite compositions
JP3494409B2 (ja) 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗がん剤として有用なアルキニル置換キノリン−２−オン誘導体
HK1039123A1 (zh) 1998-08-27 2002-04-12 辉瑞产品公司 用作抗癌剂的炔基取代的喹啉-2-酮衍生物
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
ES2200591T3 (es) 1998-12-23 2004-03-01 Janssen Pharmaceutica N.V. Derivados de 1,2-quinolina anelados.
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP2308833A3 (en) 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU763954B2 (en) 1999-04-28 2003-08-07 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
JP3766231B2 (ja) 1999-05-10 2006-04-12 Ｎｅｃビューテクノロジー株式会社 液晶表示装置
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
EP1173017B1 (en) 1999-08-05 2008-11-12 Sanyo Electric Co., Ltd. Image interpolating method
JP2001078113A (ja) 1999-09-06 2001-03-23 Sony Corp 映像機器および映像表示方法
US6852752B2 (en) 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
FR2803592A1 (fr) 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6692491B1 (en) 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
JP4150947B2 (ja) 2000-08-23 2008-09-17 ソニー株式会社 画像処理装置および方法、並びに記録媒体
WO2002032861A2 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
MXPA04006271A (es) 2001-12-27 2004-10-04 Theravance Inc Derivados de indolinona utiles como inhibidores de la proteina cinasa.
JP4218249B2 (ja) 2002-03-07 2009-02-04 株式会社日立製作所 表示装置
IL165264A0 (en) 2002-05-23 2005-12-18 Cytopia Pty Ltd Protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
AU2003258491A1 (en) 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
EP1549614A4 (en) 2002-10-03 2008-04-16 Targegen Inc VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
US20080207617A1 (en) 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
US7838527B2 (en) 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
DK1572154T3 (da) 2002-11-18 2012-05-14 Univ Rutgers Medicinske indretninger, der anvender nye polymerer
MXPA05005329A (es) 2002-11-19 2005-08-16 Univ Pennsylvania Construcciones y composiciones geneticas las cuales comprenden rre y cte y usos de las mismas.
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
CA2521830A1 (en) 2003-04-09 2004-10-21 Japan Tobacco Inc. Heteroaromatic pentacyclic compound and medicinal use thereof
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
EP1631560A2 (en) * 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
RU2345981C2 (ru) 2003-07-28 2009-02-10 Смитклайн Бичем Корпорейшн ЦИКЛОАЛКИЛИДЕНОВЫЕ СОЕДИНЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ИХ ПРИМЕНЕНИЕ И СПОСОБ СЕЛЕКТИВНОГО СВЯЗЫВАНИЯ ERα- И ERβ-ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ
CA2542909C (en) 2003-10-23 2012-07-10 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
NZ548884A (en) 2004-01-30 2010-06-25 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
JP4628770B2 (ja) 2004-02-09 2011-02-09 株式会社日立製作所 照明装置を備えた画像表示装置及び画像表示方法
JP2006084710A (ja) 2004-09-15 2006-03-30 Toshiba Matsushita Display Technology Co Ltd 表示制御回路、表示制御方法、および液晶表示装置
US20060132383A1 (en) 2004-09-27 2006-06-22 Idc, Llc System and method for illuminating interferometric modulator display
US7662837B2 (en) 2004-10-22 2010-02-16 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
JP5008569B2 (ja) 2004-10-22 2012-08-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼのインヒビターとしての芳香族アミド
ES2611604T3 (es) 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
JP4904783B2 (ja) 2005-03-24 2012-03-28 ソニー株式会社 表示装置及び表示方法
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
EP1951234A2 (en) 2005-10-18 2008-08-06 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
WO2007056163A2 (en) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101360740A (zh) 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
JP4950480B2 (ja) 2005-11-22 2012-06-13 東芝モバイルディスプレイ株式会社 液晶表示装置
KR100815916B1 (ko) 2006-02-09 2008-03-21 엘지.필립스 엘시디 주식회사 액정 표시장치의 구동장치 및 구동방법
KR101367646B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제
KR101367645B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
AU2007240439B2 (en) 2006-04-20 2012-10-11 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JP2008096956A (ja) 2006-09-15 2008-04-24 Olympus Corp 画像表示方法および画像表示装置
JP4479709B2 (ja) 2006-10-27 2010-06-09 セイコーエプソン株式会社 画像表示装置、画像表示方法、画像表示プログラム、及び画像表示プログラムを記録した記録媒体、並びに電子機器
TWI354960B (en) 2006-11-07 2011-12-21 Realtek Semiconductor Corp Method for controlling display device
JP4285532B2 (ja) 2006-12-01 2009-06-24 ソニー株式会社 バックライト制御装置、バックライト制御方法、および液晶表示装置
JP5117762B2 (ja) 2007-05-18 2013-01-16 株式会社半導体エネルギー研究所 液晶表示装置
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2215482A2 (en) 2007-10-31 2010-08-11 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
BRPI0914855A2 (pt) 2008-06-27 2019-09-24 Sharp Kk dispositivo de controle para dispositivo de exibição de cristal líquido, dispositivo de exibição de cristal líquido, método para controle de dispositivo de exibição de cristal líquido, programa e meio de armazenameto.

Also Published As

Publication number Publication date
KR101406877B1 (ko) 2014-06-13
US20160122334A1 (en) 2016-05-05
CA2649924C (en) 2014-08-19
ES2566772T3 (es) 2016-04-15
WO2007124322A1 (en) 2007-11-01
US9266866B2 (en) 2016-02-23
AR060612A1 (es) 2008-07-02
NZ572072A (en) 2011-09-30
CN101472914B (zh) 2015-05-20
ES2565238T3 (es) 2016-04-01
AR060611A1 (es) 2008-07-02
JP2009534406A (ja) 2009-09-24
US20140329815A1 (en) 2014-11-06
RU2008145763A (ru) 2010-05-27
CA2650057C (en) 2014-07-29
AU2007240442A1 (en) 2007-11-01
AU2007240443B2 (en) 2012-11-01
BRPI0710548B8 (pt) 2021-05-25
US8859602B2 (en) 2014-10-14
CA2649739C (en) 2015-09-01
EP2016074A1 (en) 2009-01-21
US20070249608A1 (en) 2007-10-25
KR20090003343A (ko) 2009-01-09
JP5331679B2 (ja) 2013-10-30
US20140200245A1 (en) 2014-07-17
AU2007240440A1 (en) 2007-11-01
US20140378457A1 (en) 2014-12-25
US8815867B2 (en) 2014-08-26
US20070249685A1 (en) 2007-10-25
US9403804B2 (en) 2016-08-02
NO20084896L (no) 2009-01-12
JP5331681B2 (ja) 2013-10-30
EP2016070B1 (en) 2016-01-13
US9394289B2 (en) 2016-07-19
AU2007240440B2 (en) 2012-09-20
AU2007240442B2 (en) 2012-09-06
RU2475483C2 (ru) 2013-02-20
BRPI0710548B1 (pt) 2020-03-24
SG171593A1 (en) 2011-06-29
MX2008013531A (es) 2009-01-20
IL194845A (en) 2014-11-30
NZ572070A (en) 2011-09-30
AR060610A1 (es) 2008-07-02
JP2009534405A (ja) 2009-09-24
TWI411612B (zh) 2013-10-11
TW200815415A (en) 2008-04-01
CA2649739A1 (en) 2007-11-01
JP2009534407A (ja) 2009-09-24
PE20080074A1 (es) 2008-02-11
EP2016058B1 (en) 2016-01-06
JP5331680B2 (ja) 2013-10-30
HK1133878A1 (en) 2010-04-09
KR101491564B1 (ko) 2015-02-09
AU2007240443A1 (en) 2007-11-01
EP2016070A1 (en) 2009-01-21
EP2016058A1 (en) 2009-01-21
MX2008013530A (es) 2009-01-14
CN101472914A (zh) 2009-07-01
WO2007124319A1 (en) 2007-11-01
ZA200809873B (en) 2010-02-24
KR101367646B1 (ko) 2014-02-27
TW200815414A (en) 2008-04-01
KR20080110917A (ko) 2008-12-19
EP2016074B1 (en) 2016-01-13
ES2564781T3 (es) 2016-03-29
WO2007124321A1 (en) 2007-11-01
KR20090015066A (ko) 2009-02-11
IL194845A0 (en) 2009-08-03
UY30297A1 (es) 2007-08-31
TW200806659A (en) 2008-02-01
MX2008013529A (es) 2009-01-15
CA2649924A1 (en) 2007-11-01
NZ572071A (en) 2011-12-22
US8722718B2 (en) 2014-05-13
US20070249680A1 (en) 2007-10-25
CA2650057A1 (en) 2007-11-01
BRPI0710548A2 (pt) 2012-06-05

Similar Documents

Publication Publication Date Title
UA93085C2 (en) Inhibitors of c-fms kinase
PT2021335E (pt) Compostos heterocíclicos como inibidores de c-fms quinase
JO3240B1 (ar) c-fms مثبطات كيناز
UA88648C2 (en) Inhibitors of c-fms kinase
ATE437864T1 (de) Aromatische amide als hemmer der c-fms-kinase
ECSP077409A (es) Inhibidores de la c-fms cinasa
EA201400575A1 (ru) Способы получения ингибиторов jak киназ и родственных промежуточных соединений
ES2667847T3 (es) Pirimidinas sustituidas útiles como inhibidores de cinasa de EGFR-T790M
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
EA018512B1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
GEP201706639B (en) Heterocyclic compounds and uses thereof
GEP20135991B (en) 2-carboxamide-pyrrolidine-amide urea derivatives substituted with pyrimidine-4-yl, and usage thereat treatment of diseases caused by phosphatidyl inositol 3-kinase
BRPI0409903A (pt) 5,7-diamino-pirazol[4,3-d]pirimidina úteis no tratamento de hipertensão
NZ600881A (en) Pyrazole derivatives as jak inhibitors
UA94622C2 (en) Kinase innhibitor
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MY153261A (en) Pyridiazinone derivatives for tumour treatment
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
AU2011334173A1 (en) Quinazoline carboxamide azetidines
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
MX2011012629A (es) Inhibidores de actividad de cinasa tipo pirimidina.
MX2022014351A (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
MX2011012632A (es) Inhibidores de actividad de cinasa tipo pirimidina.
SG10201902903RA (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
TH148533A (th) ตัวยับยั้ง c-fms ไคเนส